NCT02863666 (VPAC) is a clinical trial in Shortness of Breath Episode, sponsored by Zoll Medical Corporation.

Who is sponsoring NCT02863666?

NCT02863666 is sponsored by Zoll Medical Corporation.

What condition does NCT02863666 study?

NCT02863666 studies Shortness of Breath Episode, Tachycardia, Bradycardia, Difficulty Breathing.

Is NCT02863666 still recruiting?

NCT02863666 is currently completed. Last updated 13 May 2024.

Are results published for NCT02863666?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-05-13 · How we verify

NCT02863666: VPAC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Verification of Prediction Algorithm

Completed Results posted Last updated 13 May 2024

What this trial tests

trial in Shortness of Breath Episode in 673 participants. Completed in 15 December 2017.

Timeline

11 August 2016

Primary endpoint
13 December 2017

15 December 2017

Quick facts

Lead sponsor	Zoll Medical Corporation
Status	Completed
Study type	OBSERVATIONAL
Enrollment	673
Start date	11 August 2016
Primary completion	13 December 2017
Estimated completion	15 December 2017
Sites	3 locations across Belgium, United States

Conditions studied

Shortness of Breath Episode — all drugs for Shortness of Breath Episode →
Tachycardia — all drugs for Tachycardia →
Bradycardia — all drugs for Bradycardia →
Difficulty Breathing — all drugs for Difficulty Breathing →

Sponsor

Zoll Medical Corporation — full company profile →

Who can join

18 and older, any sex, with Shortness of Breath Episode or Tachycardia. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Subjects With a Cardiopulmonary Event Primary · Within 72 hours of presentation to ED

The number of any cardiopulmonary event, not limited to: Cardiac arrest Sustained ventricular tachycardia (VT) Hypotension requiring inotropes or intra-aortic balloon pump (IABP) insertion Intubation or mechanical ventilation Complete heart block Bradycardia requiring insertion of a pacing wire or external pacing, and Percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG)

Group	Value	95% CI
Enrolled	145

Adverse events — posted to ClinicalTrials.gov

Time frame: 1 year, 4 months. Reporting threshold: 1%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Enrolled

Serious: 0/673 (0%)

Deaths: 0/673

Other adverse events (1 terms — click to expand)

Reaction	System	Enrolled
Respiratory	Respiratory, thoracic and mediastinal disorders	—

Data from ClinicalTrials.gov NCT02863666 adverse events section.

Sponsor's own description

Prospective observational clinical study to verify an algorithm used to predict cardiopulmonary events in patients presenting to the emergency department.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Zoll Medical Corporation trials

Trials by the same sponsor.

NCT06313840 — Central Sleep Apnea Prevalence and Impact on Cognitive Function in Patients With Heart Failure With Reduced or Mildly Re · completed
NCT05505136 — Mobile Cardiac Telemetry and Advanced Multi-Parameter Monitoring in PatientS Wearing a Novel Device With Biometric Based · completed
NCT05604430 — Pre-hospital Ventilation Clinical Study · enrolling by invitation
NCT05073354 — Rapid Treatment of Shock Without Trauma · completed
NCT05013333 — AED 3 Post-Approval Study · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02863666 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zoll Medical Corporation
Last refreshed: 13 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02863666.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing